TremRx Logo

Proprietary Technology

TremRx’s technology platform is designed to create novel vaccines that are able to activate the T-cell arm of the immune system to create a strong and effective immune response. Whereas many conventional vaccines are designed specifically to activate the humoral or B-cell arm of the immune system and create disease-fighting antibodies, TremRx’s vaccines aim to primarily engage the cell-mediated or T-cell arm of the immune system which is an efficient path to fighting disease by directly destroying the infected cells. TremRx’s approach enables activation of a strong immune response mediated by a unique population of protective memory T cells (TREM) that reside in both skin and other epithelial tissues, the body’s interfaces to the environment and the typical entry point for disease-causing organisms.

TremRx designs novel prophylactic and therapeutic vaccines based on the following key factors and technology capabilities:

Vaccines with replication-deficient virus: TremRx’s technology platform engineers viruses that are replication-deficient, in a manner than produces a strong immune response against disease. By using a replication-deficient viral vector, TremRx’s vaccines may have significant safety advantages since many in a vaccinated population are young children or immune impaired individuals. The unique combination of TremRx’s vaccines with replication-deficient viruses and epidermal delivery has the potential to provide orders of magnitude more T-cell based protection than replicating viruses delivered by any other means.

Vaccines designed for epidermal delivery: TremRx designs its vaccines to be delivered to cells in the top layer of abraded skin. This novel approach of delivering a vaccine to keratinocytes and other epidermal cells sets off a cascade that creates large populations of T Resident Effector Memory cells (TREMs) in epithelial tissues that provide strong protective immunity. This route of vaccination is far more effective at creating Trem than any route of vaccination. In addition, it is a superior way of generating robust antibody and circulating T cell responses.

Viral vectors: TremRx’s technology platform has the flexibility to engineer vaccines with a range of viral vectors.

  • Vaccinia vector: To date, studies have focused on the use of replication-deficient vaccinia vectors, which have been shown to be highly effective at infecting epidermal keratinocytes and are also readily engineered to express large payloads. These are favorable characteristics that make vaccinia vectors ideally suited to form the basis of highly-protective TremRx vaccines that can be delivered epidermally.

Small pox vaccine of the 1700s

The first successful vaccine to be developed was the small pox vaccine, discovered by Edward Jenner in 1796. Since syringes had not yet been invented, Jenner administered this first vaccine by disrupting the upper layers of skin with a needle, which remained the route of administration for the most effective vaccine in medical history which ultimately eliminated smallpox, one of the most devastating plagues in history. In essence, Jenner stumbled upon the ideal route of administration for a live-virus vaccine: epidermal scarification and infection. Now, with the discoveries of TremRx scientific founder, Dr. Thomas Kupper, we understand that Jenner's success resulted from the generation of T Resident Effector Memory cells (TREMs) in multiple epithelial tissues. We now know that this result can also be induced by engineered replication-deficient viruses.